Subscribe to RSS
DOI: 10.1055/s-2008-1038950
© Georg Thieme Verlag KG Stuttgart · New York
Serum Transforming Growth Factor-β1 and Epidermal Growth Factor in Biliary Atresia
Publication History
received June 23, 2008
accepted after revision July 7, 2008
Publication Date:
14 November 2008 (online)
Abstract
Background and Aim: Biliary atresia (BA) is a serious liver disease in children. Since transforming growth factor-β1 (TGF-β1) and epidermal growth factor (EGF) are involved in the hepatic reparative process, our objective was to investigate whether serum TGF-β1 and serum EGF levels were associated with therapeutic outcomes in BA. Methods: Serum levels of TGF-β1 and EGF were determined with the ELISA method in 67 postoperative BA patients with a median age of 7 years and in 10 age-comparable healthy children. The BA patients were then divided into two groups depending on their therapeutic outcome: good outcome (jaundice-free) and poor outcome (persistent jaundice). Clinical data, serum TGF-β1 and serum EGF levels were compared between the two groups of BA patients. Correlation analysis of serum TGF-β1 with serum EGF was carried out. Data are expressed as mean ± SD. Results: Serum TGF-β1 levels of BA patients were higher than those of controls (86.6 ± 15.7 vs. 75.7 ± 8.8 ng/ml, p = 0.0362). However, there was no difference in serum EGF between BA patients and controls (133.1 ± 66.6 vs. 125.4 ± 88.9 pg/ml, p = 0.744). Further subgroup analysis showed that patients with good outcomes (n = 40) had higher serum TGF-β1 and serum EGF levels than patients with poor outcomes (TGF-β1: 91.2 ± 16.5 vs. 79.6 ± 11.7 ng/ml, p = 0.002; EGF: 148.5 ± 65.0 vs. 110.3 ± 63.4 pg/ml, p = 0.02). In addition, serum TGF-β1 was positively correlated with serum EGF (Pearson's r = 0.3418, p = 0.0046). Conclusion: Elevated serum TGF-β1 and serum EGF levels were associated with a good outcome in BA patients. There was a positive correlation between serum TGF-β1 and serum EGF. This suggests that the resultant TGF-β1 and EGF pathways may be involved in the pathophysiological process in postoperative BA.
Key words
biliary atresia - TGF - EGF
References
- 1 Berlanga J, Caballero M E, Ramirez D. et al . Epidermal growth factor protects against carbon tetrachloride-induced hepatic injury. Clin Sci (Lond). 1998; 94 219-223
- 2 Bissig K D, Marti U, Solioz M. et al . Epidermal growth factor is decreased in liver of rats with biliary cirrhosis but does not act as paracrine growth factor immediately after hepatectomy. J Hepatol. 2000; 33 275-281
- 3 Deneme M A, Ok E, Akcan A, Akyildiz H, Soyuer I, Muhtaroglu S. Single dose of anti-transforming growth factor-beta1 monoclonal antibody enhances liver regeneration after partial hepatectomy in biliary-obstructed rats. J Surg Res. 2006; 136 280-287
- 4 Hashimoto M, Kothary P C, Eckhauser F E, Raper S E. Treatment of cirrhotic rats with epidermal growth factor and insulin accelerates liver DNA synthesis after partial hepatectomy. J Gastroenterol Hepatol. 1998; 13 1259-1265
- 5 Honsawek S, Chongsrisawat V, Vejchapipat P, Thawornsuk N, Tangkijvanich P, Poovorawan Y. Serum interleukin-8 in children with biliary atresia: relationship with disease stage and biochemical parameters. Pediatr Surg Int. 2005; 21 73-77
- 6 Kayano K, Okita K. Does IL‐6 regulate liver fibrosis/cirrhosis directly and indirectly?. J Gastroenterol. 2000; 35 250-251
- 7 Kelly D A, Davenport M. Current management of biliary atresia. Arch Dis Child. 2007; 92 1132-1135
- 8 Kirmaz C, Terzioglu E, Topalak O. et al . Serum transforming growth factor-beta1(TGF-beta1) in patients with cirrhosis, chronic hepatitis B and chronic hepatitis C [corrected]. Eur Cytokine Netw. 2004; 15 112-116
- 9 Kiyama S, Yamada T, Iwata H. et al . Reduction of fibrosis in a rat model of non-alcoholic steatohepatitis cirrhosis by human HGF gene transfection using electroporation. J Gastroenterol Hepatol. 2008; 23 e471-e576
- 10 Kobayashi H, Horikoshi K, Long L, Yamataka A, Lane G J, Miyano T. Serum concentration of adhesion molecules in postoperative biliary atresia patients: relationship to disease activity and cirrhosis. J Pediatr Surg. 2001; 36 1297-1301
- 11 Kobayashi H, Hayashi N, Hayashi K, Yamataka A, Lane G J, Miyano T. Connective tissue growth factor and progressive fibrosis in biliary atresia. Pediatr Surg Int. 2005; 21 12-16
- 12 Kobayashi H, Horikoshi K, Yamataka A. et al . Are stable postoperative biliary atresia patients really stable?. Pediatr Surg Int. 2001; 17 104-107
- 13 Komuves L G, Feren A, Jones A L, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000; 48 821-830
- 14 Liu C, Chiu J-H, Chin T. et al . Expression of Fas ligand on bile ductule epithelium in biliary atresia – a poor prognostic factor. J Pediatr Surg. 2000; 35 1591-1596
- 15 Malizia G, Brunt E M, Peters M G, Rizzo A, Broekelmann T J, McDonald J A. Growth factor and procollagen type I gene expression in human liver disease. Gastroenterology. 1995; 108 145-156
- 16 Mitsue S, Hamanoue M, Tanabe G. et al . Expression of HGF and TGF-beta 1 mRNA after partial hepatectomy in rats with liver cirrhosis. Surg Today. 1995; 25 237-243
- 17 Moreira R K. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med. 2007; 131 1728-1734
- 18 Napoli J, Prentice D, Niinami C, Bishop G A, Desmond P, McCaughan G W. Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor beta in a bile duct ligated rat model of cirrhosis. Hepatology. 1997; 26 624-633
- 19 Ohi R. Biliary atresia. A surgical perspective. Clin Liver Dis. 2000; 4 779-804
- 20 Ohi R. Surgery for biliary atresia. Liver. 2001; 21 175-182
- 21 Ramm G A, Nair V G, Bridle K R, Shepherd R W, Crawford D H. Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia. Am J Pathol. 1998; 153 527-535
- 22 Skov Olsen P, Boesby S, Kirkegaard P. et al . Influence of epidermal growth factor on liver regeneration after partial hepatectomy in rats. Hepatology. 1988; 8 992-996
- 23 Uchida K, Inoue M, Otake K. et al . The significance of serum hepatocyte growth factor levels in planning follow-up of postoperative jaundice-free patients with biliary atresia. J Pediatr Surg. 2006; 41 1657-1662
- 24 Ueno T, Nakamura T, Torimura T, Sata M. Angiogenic cell therapy for hepatic fibrosis. Med Mol Morphol. 2006; 39 16-21
- 25 Vejchapipat P, Theamboonlers A, Chaokhonchai R, Chongsrisawat V, Chittmittrapap S, Poovorawan Y. Serum hepatocyte growth factor and clinical outcome in biliary atresia. J Pediatr Surg. 2004; 39 1045-1049
- 26 Yang C, Zeisberg M, Mosterman B. et al . Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology. 2003; 124 147-159
- 27 Yoshida S, Nio M, Hayashi Y, Ohi R, Kawamura I, Goto T. Serum insulinlike growth factor-I in biliary atresia. J Pediatr Surg. 2003; 38 211-215
Dr. M.D., Ph.D. Paisarn Vejchapipat
Department of Surgery
Chulalongkorn Hospital
Rama IV road, Patumwan
10330 Bangkok
Thailand
Email: pvejchap@yahoo.co.uk